Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.

Rovner ES, Raymond K, Andruczyk E, Juul KV

Lower urinary tract symptoms31 May 2017Cited by 22 (Europe PMC)

PMID28560762DOI10.1111/luts.12169PepBankPUB-28560762

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with overactive bladder and nocturia, added desmopressin did not significantly reduce nocturnal voids versus tolterodine alone.
In plain wordsIn women with overactive bladder, desmopressin plus tolterodine did not significantly reduce night-time urination compared with tolterodine alone.
Peptide
Desmopressin
Outcome
No significant changeNocturnal voids
Study
n: not reported in source
Comparator
tolterodine plus placebo ODT
Analysis
Primary
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Measurements
Adjusted treatment contrast
−0.34 voids
reported result
P value
0.112 unitless
reported result
Source sentences
Summary
Overall population showed a non-significant reduction in mean number of nocturnal voids with combination versus monotherapy (full analysis set: adjusted treatment contrast [TC], -0.34; P = 0.112).
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076201
02HumanRandomized controlled trialEfficacy outcome
In women with overactive bladder, added desmopressin did not significantly change nocturnal void volume versus tolterodine alone.
In plain wordsIn women with overactive bladder, added desmopressin did not significantly change night-time urine volume compared with tolterodine alone.
Peptide
Desmopressin
Outcome
No significant changeNocturnal void volume
Study
n: not reported in source
Comparator
tolterodine plus placebo ODT
Analysis
Secondary
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Measurements
Treatment contrast
−64.16 mL
reported result
P value
0.103 unitless
reported result
Source sentences
Summary
Change in mean nocturnal void volume (TC, -64.16 mL; P = 0.103), mean time to first nocturnal void (TC, 18.00 min; P = 0.385) and Nocturia Impact (NI) Diary^© scores were comparable.
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076202
03HumanRandomized controlled trialEfficacy outcome
In women with overactive bladder, added desmopressin did not significantly change first nocturnal void time versus tolterodine alone.
In plain wordsIn women with overactive bladder, added desmopressin did not significantly delay first night-time urination compared with tolterodine alone.
Peptide
Desmopressin
Outcome
No significant changeTime to first nocturnal void
Study
n: not reported in source
Comparator
tolterodine plus placebo ODT
Analysis
Secondary
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Measurements
Treatment contrast
18 min
reported result
P value
0.385 unitless
reported result
Source sentences
Summary
Change in mean nocturnal void volume (TC, -64.16 mL; P = 0.103), mean time to first nocturnal void (TC, 18.00 min; P = 0.385) and Nocturia Impact (NI) Diary^© scores were comparable.
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076203
04HumanRandomized controlled trialEfficacy outcome
In women with overactive bladder, Nocturia Impact Diary scores were comparable with added desmopressin and tolterodine alone.
In plain wordsIn women with overactive bladder, nocturia impact scores were similar with added desmopressin and tolterodine alone.
Peptide
Desmopressin
Outcome
Direction not reportedNocturia Impact Diary score
Study
n: not reported in source
Comparator
tolterodine plus placebo ODT
Analysis
Secondary
Outcome group
Quality of life · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Source sentences
Summary
Change in mean nocturnal void volume (TC, -64.16 mL; P = 0.103), mean time to first nocturnal void (TC, 18.00 min; P = 0.385) and Nocturia Impact (NI) Diary^© scores were comparable.
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076204
05HumanRandomized controlled trialEfficacy outcome
In women with overactive bladder and nocturnal polyuria, added desmopressin improved nocturnal void volume versus tolterodine alone.
In plain wordsIn women with nocturnal polyuria, added desmopressin improved night-time urine volume compared with tolterodine alone.
Peptide
Desmopressin
Outcome
Direction not reportedNocturnal void volume in nocturnal polyuria subgroup
Study
n = 47
Comparator
tolterodine plus placebo ODT
Analysis
Exploratory
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Measurements
P value
0.034 unitless
reported result
Source sentences
Summary
In post-hoc analysis, NP patients showed a benefit with combination versus monotherapy for nocturnal void volume (P = 0.034) and time to first nocturnal void (P = 0.045), and a non-significant improvement in NI Diary^© scores.
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076205
06HumanRandomized controlled trialEfficacy outcome
In women with overactive bladder and nocturnal polyuria, added desmopressin improved first nocturnal void time versus tolterodine alone.
In plain wordsIn women with nocturnal polyuria, added desmopressin improved the time to first night-time urination compared with tolterodine alone.
Peptide
Desmopressin
Outcome
Direction not reportedTime to first nocturnal void in nocturnal polyuria subgroup
Study
n = 47
Comparator
tolterodine plus placebo ODT
Analysis
Exploratory
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Measurements
P value
0.045 unitless
reported result
Source sentences
Summary
In post-hoc analysis, NP patients showed a benefit with combination versus monotherapy for nocturnal void volume (P = 0.034) and time to first nocturnal void (P = 0.045), and a non-significant improvement in NI Diary^© scores.
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076206
07HumanRandomized controlled trialEfficacy outcome
In women with nocturnal polyuria, added desmopressin did not significantly improve Nocturia Impact Diary scores versus tolterodine alone.
In plain wordsIn women with nocturnal polyuria, added desmopressin did not significantly improve nocturia impact scores compared with tolterodine alone.
Peptide
Desmopressin
Outcome
No significant changeNocturia Impact Diary score in nocturnal polyuria subgroup
Study
n = 47
Comparator
tolterodine plus placebo ODT
Analysis
Exploratory
Outcome group
Quality of life · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Source sentences
Summary
In post-hoc analysis, NP patients showed a benefit with combination versus monotherapy for nocturnal void volume (P = 0.034) and time to first nocturnal void (P = 0.045), and a non-significant improvement in NI Diary^© scores.
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076207
08HumanRandomized controlled trialSafety outcome
In women with overactive bladder, safety profiles were comparable with added desmopressin and tolterodine alone.
In plain wordsIn women with overactive bladder, safety was similar with added desmopressin and tolterodine alone.
Peptide
Desmopressin
Outcome
Direction not reportedSafety profile
Study
n = 106
Comparator
tolterodine plus placebo ODT
Outcome group
Adverse events · Kidney and urinary
Studied dose
25 µg once daily · oral · 3 monthsAs given in this study (human).
Source sentences
Summary
Safety profile was comparable between treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
This double-blind, randomized, proof-of-concept study enrolled 106 patients (≥18 years), with overactive bladder (OAB) and nocturia,
Summary · context
receiving a 3-month once-daily combination (desmopressin 25 µg, orally-disintegrating tablets [ODT]/tolterodine 4 mg [Detrol® LA]; n = 49) or monotherapy (tolterodine 4 mg/placebo ODT; n = 57).
Report a problemFND-2856076208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords